Active clinical trials for "COVID-19"

This is a pilot study which aims to assess the validity and applicability of lateral flow assays (LFAs) which can be used as a point of care test for COVID-19. The study will focus on children admitted to hospital or planned to have a procedure for which they require an anaesthetic. RT-PCR is the current gold standard test for COVID-19, but it usually takes approximately 24-48 hours for a test result to be returned which can slow the clinical care given to a patient and can potentially increase the risk of healthcare worker (HWC) exposure to COVID-19. LFAs are a point of care test which can identify children who have a high viral load of COVID-19 and are performed using a more acceptable method of swabbing for children, just inside the nostril. Using LFA potentially enables the identification of infectious children with COVID-19 to aid with immediate care of patients and limiting HWC and other patients' contact with the virus. This study aims to assess the test failure rate and identify reasons for this which can be addressed. It also aims to assess the discomfort of both tests for children, provide a comparison between the time to LCA and RT-PCR result and provide data for a trial to adequately power a prospective trial comparing RT-PCR and LFA.

The primary objectives of this pilot study protocol are to assess safety and feasibility of using the geko™ device in COVID-19. Regarding safety to patients, we will measure the rate of adverse events, primarily local site irritation or discomfort. Feasibility will be measured on the basis of recruitment; ability to enroll sufficient number of patients meeting criteria. Protocol adherence will be observed as the ability to deliver the study intervention to the patients randomized to the treatment arm within the prescribed timeline and ability to complete the course of treatment. Additionally, we plan to measure patient outcomes such as ICU admission and death. The findings of this study have the potential to decrease the complications seen in COVID-19 infections.

The objective is to determine the safety and immunogenicity of two different strengths (3 µg and 6 µg) of an inactivated COVID 19 Vaccine compared to placebo so that to demonstrate the safety and efficacy in prophylaxis of COVID-19.

The purpose of this study is to describe the immunological and virological response of patients infected with CoV-2-SARS and presenting an asymptomatic or mildly symptomatic form, in particular the innate and adaptive response as well as the virological clearance kinetics. The research hypothesis is that patients with an ambulatory form of SARS-CoV-2 infection, whether asymptomatic or mildly symptomatic, are able to mount an innate and adaptive immunological response capable of rapidly clearing the virus, in contrast to severe forms in which an early deficit of type 1 IFN response has been demonstrated, possibly responsible for a defect in the control of viral replication in the blood.

This is prospective double-blind study in the United States is designed to investigate the efficacy and safety of a single dose of COVI-DROPS or matched placebo in outpatient adults with mild symptoms associated with COVID-19 and a recent positive COVID-19 test.

Stereotype threat (ST) is an important issue that has been studied repeatedly in the psychology literature. ST is the thought that a person will be negatively evaluated and judged regarding a negative stereotype that belongs to the group to which he/she belongs. Most people are members of a social group associated with at least one negative stereotype. Therefore, many people in society may be the target of stereotype threat. Previous research has shown that the individual performance of people in groups identified with negative stereotypes, who are exposed to stereotype threat, decreases. The ST may arise when there is an environment in which the skills of the person that may be affected by a stereotype associated with his/her group can be measured, or if this stereotype has become evident. In Covid-19, there has been a rapid increase in the number of intensive care patients in our country and around the World. Due to this rapid increase, the number of intensivist physicians is insufficient, and non-intensivist physicians from various branches are assigned to intensive care units. In social media and newspaper reports, it was stated that non-intensivist physicians have insufficient knowledge and skills in intubation and in the treatment of lung infection, and the public was asked to take precautions. However, these physicians were expected to treat lung infections and intubate the patients in intensive care units during pandemics. It is unknown to what extent such negative stereotypes, established or already existing, affect the performance of non-intensivist physicians during their appointment to the intensive care units during the pandemic. As in all other departments, the most basic task expected from doctors in intensive care units is effective basic life support applied for the treatment of cardiopulmonary arrest. Cardiopulmonary resuscitation (CPR) is a basic life support model that is mandatory taught in medical schools. For this reason, it is expected that all doctors, regardless of their specialties, will be able to perform CPR effectively. The use of manikins is quite common in order to standardize CPR training and performance measurement. The aim of this study is to evaluate how non-intensivist physicians assigned to intensive care units during the pandemic are affected by stereotype threat and to investigate the necessary conditions to prevent a possible decrease in performance in these physicians.

The multicenter, double-blind, placebo-controlled, parallel-group, randomized clinical trial. The objective of this study is to evaluate the efficacy and safety of Ergoferon as a non-specific preventive medicine for COVID-19 in individuals vaccinated against a new coronavirus infection (SARS-CoV-2)

This is a phase II, randomized, two-armed, double-blind, placebo-controlled trial designed to evaluate the safety, tolerability, and immunogenicity of a candidate adjuvanted recombinant SARS-CoV-2 spike (S) protein subunit vaccine (SpikoGen) produced by CinnaGen Co. 400 adult individuals receive either SARS-CoV-2 recombinant spike protein (25 µg) with Advax-SM adjuvant (15 mg) or saline placebo in a 3:1 ratio. The injection is given in two doses with a 21-day interval in the deltoid muscle of the non-dominant arm. The randomization was stratified by age (<65 or ≥65) and health conditions of potential risk for severe COVID-19. Participants will be visited at two weeks and will be followed up for six months after the second dose of the study intervention. Study hypotheses include: The adjuvanted COVID-19 vaccine candidate is safe and tolerable in adult subjects. The adjuvanted COVID-19 vaccine candidate induces strong immunogenicity against SARS-CoV-2 in adult subjects.

This sub-study is a prospective open-label, single-center study to demonstrate comparability of different manufacturing scales.

This is a phase 2 randomized, double-blind clinical trial testing an anti-SARS-CoV-2 COVID-19 vaccine (AV-COVID-19) made on site using PT AIVITA Biomedika Indonesia's vaccine-enabling kit for the prevention of COVID-19 infection. The product is a subject-specific personal vaccine that consists of autologous dendritic cells and lymphocytes (DCL) previously incubated with a quantity of SARS-CoV-2 spike protein (S-protein) which was shown to be safe in a phase 1 study also conducted in Indonesia. In this phase 2 study, efficacy is assessed via enhanced S-protein-specific T-cell response by comparing results before and after vaccination. Safety is confirmed via laboratory values, observation and regular patient reporting.